Aligos Therapeutics (ALGS) Shares Outstanding (Diluted Average) (2021 - 2026)

Aligos Therapeutics has reported Shares Outstanding (Diluted Average) for 6 years, with the latest figure at $10.4 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 19.44% year-over-year to $10.4 million; the trailing twelve-month figure through Mar 2026 stood at $10.4 million (up 19.44% YoY), and the FY2025 full-year result was $9.9 million, up 57.79% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $10.4 million, up from $9.9 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $156.3 million in Q2 2024, with the low at $1.7 million in Q3 2023.
• Historically, Shares Outstanding (Diluted Average) has averaged $39.0 million across 5 years, with a median of $26.5 million in 2022.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Diluted Average) tumbled 95.96% — and 2024, when it soared 263.91%.
• Aligos Therapeutics' Shares Outstanding (Diluted Average) stood at $42.7 million in 2022, then tumbled by 94.0% to $2.6 million in 2023, then soared by 144.38% to $6.3 million in 2024, then soared by 57.79% to $9.9 million in 2025, then increased by 5.24% to $10.4 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $10.4 million (Q1 2026), $9.9 million (Q4 2025), and $9.7 million (Q3 2025), per Business Quant data.